Pieris Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information - Schedule of Reconciles Segment Direct Profit or Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Total research and development	$ 8,151	$ 8,793
Total general and administrative	5,944	3,076
Operating loss	(14,095)	(11,869)
QTORIN Rapamycin for PC and GS [Member]
Segment Reporting Information [Line Items]
Total research and development		3,682
QTORIN Rapamycin for Microcystic LM [Member]
Segment Reporting Information [Line Items]
Total research and development	1,929	164
QTORIN Rapamycin for Microcystic LM - Government Grant Income [Member]
Segment Reporting Information [Line Items]
Total research and development	(141)
QTORIN Rapamycin For Cutaneous VM [Member]
Segment Reporting Information [Line Items]
Total research and development	296
QTORIN Rapamycin CMC [Member]
Segment Reporting Information [Line Items]
Total research and development	1,601	878
Salaries and Stock-based Compensation [Member]
Segment Reporting Information [Line Items]
Total research and development	2,810	2,383
Total general and administrative	1,935	821
Consultants [Member]
Segment Reporting Information [Line Items]
Total research and development	1,040	1,229
Total general and administrative	2,961	605
Other [Member]
Segment Reporting Information [Line Items]
Total research and development	616	457
Total general and administrative	$ 1,048	$ 1,650